Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 617

Results For "NAL"

6227 News Found

Lonza and Immunitas announce manufacturing agreement
News | April 18, 2021

Lonza and Immunitas announce manufacturing agreement

Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies


Pharma sector has both brainpower and manpower to drive growth: Mandaviya
Policy | April 09, 2021

Pharma sector has both brainpower and manpower to drive growth: Mandaviya

The government has taken all the effective measures to make healthcare affordable


Zydus Cadila announces USFDA approval for Ibrutinib capsules
News | April 08, 2021

Zydus Cadila announces USFDA approval for Ibrutinib capsules

Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.


Panacea to produce 100 mn doses of Sputnik V vaccine
News | April 06, 2021

Panacea to produce 100 mn doses of Sputnik V vaccine

Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF


Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities
News | April 05, 2021

Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities

ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E


Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
News | April 05, 2021

Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19

PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents


Reports on GSK Pharmaceuticals by ICICI Securities
News | April 03, 2021

Reports on GSK Pharmaceuticals by ICICI Securities

GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn


Lonza completes divestment of two sites to NextPharma
News | April 02, 2021

Lonza completes divestment of two sites to NextPharma

Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies


Promoters of Lincoln Pharma increases holding by 4.9%
News | April 01, 2021

Promoters of Lincoln Pharma increases holding by 4.9%

The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020